Seeking Alpha

Vivus (VVUS) +6.8% premarket after a study concludes its weight-loss drug Qsymia significantly...

Vivus (VVUS) +6.8% premarket after a study concludes its weight-loss drug Qsymia significantly improved multiple cardiovascular disease risk factors. The biopharma company says patients with hypertension or high cholesterol treated with Qsymia for one year experienced significant weight loss and clinically meaningful improvements in their underlying cardiovascular risk factors.
Comments (1)
  • billchristie
    , contributor
    Comments (22) | Send Message
     
    Here is the Study published in The American Journal of Cardiology: "Changes in Cardiovascular Risk Associated With Phentermine and Topiramate Extended-Release in Participants With Comorbidities and a Body Mass Index ≥27 kg/m2."

     

    http://bit.ly/WFFTTD
    Catch me on twitter @BAMPOTSCOT
    1 Feb 2013, 10:59 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|